UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

Maintenance Therapy with Certolizumab Pegol for Crohn's Disease

The New England journal of medicine, 2007-07, Vol.357 (3), p.239-250

2007

Link zum Volltext

Verfügbarkeit prüfen

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

Scandinavian journal of gastroenterology, 2011-03, Vol.46 (3), p.310-318

2011

Link zum Volltext

Verfügbarkeit prüfen

Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study

Scandinavian journal of gastroenterology, 2012-05, Vol.47 (5), p.518-527

2012

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s Disease

Gastroenterology (New York, N.Y. 1943), 2005-09, Vol.129 (3), p.807-818

2005

Link zum Volltext

Verfügbarkeit prüfen

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

Gut, 2014-06, Vol.63 (6), p.919-927

2014

Link zum Volltext

Verfügbarkeit prüfen

Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD

Inflammatory bowel diseases, 2014-10, Vol.20 (10), p.1714-1721

2014

Link zum Volltext

Verfügbarkeit prüfen

Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

Scandinavian journal of gastroenterology, 2009, Vol.44 (7), p.774-781

2009

Link zum Volltext

Verfügbarkeit prüfen

A Comparison of Budesonide and Mesalamine for Active Crohn's Disease

The New England journal of medicine, 1998-08, Vol.339 (6), p.370-374

1998

Link zum Volltext

Verfügbarkeit prüfen

Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: The first 100 patients treated in Scandinavia

Scandinavian journal of gastroenterology, 2007, Vol.42 (2), p.221-227

2007

Link zum Volltext

Verfügbarkeit prüfen

Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: A population‐based study from Copenhagen, Denmark

Inflammatory bowel diseases, 2007-04, Vol.13 (4), p.481-489

2007

Link zum Volltext

Verfügbarkeit prüfen

A Maximum Likelihood Estimator of a Markov Model for Disease Activity in Crohn’s Disease and Ulcerative Colitis for Annually Aggregated Partial Observations

Medical decision making, 2010-01, Vol.30 (1), p.132-142

2010

Link zum Volltext

Verfügbarkeit prüfen

Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease

Vaccine, 2015-10, Vol.33 (41), p.5464-5469

2015

Link zum Volltext

Verfügbarkeit prüfen

Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease

Journal of Crohn's and colitis, 2012-02, Vol.6 (1), p.108-111

2012

Link zum Volltext

Verfügbarkeit prüfen

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2011-07, Vol.34 (1), p.51-58

2011

Link zum Volltext

Verfügbarkeit prüfen

Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up

Infectious diseases (London, England), 2019-09, Vol.51 (9), p.651-658

2019

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis and management of fistulizing Crohn's disease

Nature clinical practice. Gastroenterology & hepatology, 2009-02, Vol.6 (2), p.92-106

2009

Link zum Volltext

Verfügbarkeit prüfen

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial

BMJ open, 2014-12, Vol.4 (12), p.e005887-e005887

2014

Link zum Volltext

Verfügbarkeit prüfen

Colonoscopy surveillance for dysplasia and colorectal cancer in patients with inflammatory bowel disease

Danish medical journal, 2015-01, Vol.62 (1), p.B4995

2015

Link zum Volltext

Verfügbarkeit prüfen

A Placebo-Controlled, Double-Blind, Randomized Trial of Cyclosporine Therapy in Active Chronic Crohn's Disease

The New England journal of medicine, 1989-09, Vol.321 (13), p.845-850

1989

Link zum Volltext

Verfügbarkeit prüfen

PRECisE 2 Data Demonstrate a High Association between Work Productivity, Daily Activities and Clinical Endpoints in Crohnʼs Disease: 1024

The American journal of gastroenterology, 2006-09, Vol.101, p.S403

2006

Link zum Volltext

Verfügbarkeit prüfen

World Gastroenterology Organisation Global Guideline: Constipation—A Global Perspective

Journal of clinical gastroenterology, 2011-07, Vol.45 (6), p.483-487

2011

Link zum Volltext

Verfügbarkeit prüfen

TREATMENT OF REFRACTORY ULCERATIVE COLITIS WITH CYCLOSPORIN ENEMAS

The Lancet (British edition), 1989-04, Vol.333 (8640), p.721-722

1989

Link zum Volltext

Verfügbarkeit prüfen

Reply

Gastroenterology (New York, N.Y. 1943), 1999-05, Vol.116 (5), p.1264

Thomsen, Ole Østergaard

1999

Link zum Volltext

Verfügbarkeit prüfen

Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors

Ugeskrift for læger, 2010-01, Vol.172 (1), p.44

2010

Link zum Volltext

Verfügbarkeit prüfen

Mesalazine for maintenance of medically-induced remission in Crohn disease: a survey of a Cochrane review

Ugeskrift for læger, 2005-08, Vol.167 (33), p.3015

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(56)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(42)
Life Sciences & Biomedicine
(41)
Humans
(37)
Female
(27)
Male
(25)
Adult
(20)
Middle Aged
(19)
Gastroenterology & Hepatology
(15)
Biological And Medical Sciences
(14)
Crohn Disease - Drug Therapy
(14)
Crohn's Disease
(13)
Aged
(11)
Medical Sciences
(11)
General & Internal Medicine
(10)
Medicine, General & Internal
(10)
Gastroenterology. Liver. Pancreas. Abdomen
(9)
Infliximab
(9)
Other Diseases. Semiology
(9)
Patients
(9)
Stomach. Duodenum. Small Intestine. Colon. Rectum. Anus
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Maintenance Therapy with Certolizumab Pegol for Crohn's Disease

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study

A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s Disease

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD

Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

A Comparison of Budesonide and Mesalamine for Active Crohn's Disease

Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: The first 100 patients treated in Scandinavia

Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: A population‐based study from Copenhagen, Denmark

A Maximum Likelihood Estimator of a Markov Model for Disease Activity in Crohn’s Disease and Ulcerative Colitis for Annually Aggregated Partial Observations

Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease

Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up

Diagnosis and management of fistulizing Crohn's disease

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial

Colonoscopy surveillance for dysplasia and colorectal cancer in patients with inflammatory bowel disease

A Placebo-Controlled, Double-Blind, Randomized Trial of Cyclosporine Therapy in Active Chronic Crohn's Disease

PRECisE 2 Data Demonstrate a High Association between Work Productivity, Daily Activities and Clinical Endpoints in Crohnʼs Disease: 1024

World Gastroenterology Organisation Global Guideline: Constipation—A Global Perspective

TREATMENT OF REFRACTORY ULCERATIVE COLITIS WITH CYCLOSPORIN ENEMAS

Reply

Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors

Mesalazine for maintenance of medically-induced remission in Crohn disease: a survey of a Cochrane review

Suchergebnisse filtern